Kiley Juergens Wealth Management LLC Cuts Holdings in Novo Nordisk A/S (NYSE:NVO)

Kiley Juergens Wealth Management LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 38.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,930 shares of the company’s stock after selling 7,594 shares during the quarter. Kiley Juergens Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,026,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. Natixis Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC increased its stake in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Talbot Financial LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $4,066,000. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $86,000. Finally, Zions Bancorporation N.A. increased its position in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE NVO opened at $78.74 on Tuesday. The stock’s fifty day simple moving average is $97.76 and its two-hundred day simple moving average is $116.89. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45.

Wall Street Analyst Weigh In

NVO has been the subject of several research reports. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.